Nobody can tell you, and that is the honest answer. A compounded drug is not FDA-approved. No agency reviews it for safety, efficacy or quality before it reaches you. What can be said is what a survey of the products found. It looked at 33 semaglutide and tirzepatide preparations sold by compounding sites. Forty-eight per cent mixed the peptide with other ingredients. Only 18% published a beyond-use date. Only 28% published storage conditions.
Almost every low figure on this price desk belongs to a compounded preparation. The gap against an approved product is not a discount on the same thing. It is a different regulatory route, with a different set of things known about it. That is worth setting out plainly before any figure is compared on the price check.
What "compounded" changes
A compounded incretin does not go through FDA approval[1]. A committee convened by the American College of Clinical Pharmacy reviewed these products. It reported limited data showing positive outcomes in small cohorts. It reported significant legal and safety concerns alongside them[1]. Its practical advice was to help patients get approved medication where possible. Where a patient chooses a compounded product, use a reputable pharmacy and monitor it[1].
Three questions sit under that advice, and each has been measured separately. Whether the contents match the label — testing has found they sometimes do not. Whether the dose is the dose — dosing errors with these products are documented. Whether your own clinician knows you are taking one — often they do not.
The shortage ended, and the rules changed with it
While a drug sits on the FDA shortage list, compounders have latitude to copy it. The semaglutide and tirzepatide shortages resolved, and that latitude closed. Compounders may now sell only what is not essentially a copy. That means a different route, a different dose, or added ingredients[2]. Where those products come from is a question the rule change made sharper.
That rule is visible in what is now on sale. A search of compounding sites between February and March 2025 identified 33 unique semaglutide or tirzepatide products[2]. Two-thirds contained semaglutide and one-third tirzepatide. Forty-eight per cent added some mixture of cyanocobalamin, glycine, niacinamide, docusate or ondansetron. Of the 17 single-ingredient products, 82% were sublingual and 18% orally disintegrating tablets[2].
What the safety reporting shows
A retrospective analysis of the FDA Adverse Event Reporting System covering 2018 to 2024 examined 81,078 GLP-1 reports, of which 707 involved compounded products[3]. Compounded formulations showed higher reporting odds ratios for abdominal pain, 2.84 (95% CI 2.29 to 3.49), and for cholecystitis, 3.39 (95% CI 1.61 to 6.31)[3].
The larger differences were in how the product reached the patient rather than in the molecule. Reporting odds ran 48.92 (95% CI 12.63 to 189.6) for preparation errors and 19.00 (95% CI 4.24 to 85.03) for contamination. The odds of hospitalization were 2.35 (95% CI 1.94 to 2.83)[3]. Administration and dosing errors were reported less often for compounded products.
Why the price on a compounded page is not the price of the same thing
Nothing above says a compounded preparation does not work. It says something narrower. Whether it works as well, at the same dose, with the same impurity profile, has not been established the way it has for the approved product. The products now on sale are deliberately not the same formulation[2]. So a page setting a $99 compounded figure beside a $499 branded one is not comparing like with like. The two purchases differ in what is known about them as much as in cost. That split is visible at ShedRx, which sells both, and at WeightWatchers Clinic, which sells only the approved products.
The cited opinion names the checks a buyer can actually make. Whether the pharmacy is identified. Whether a beyond-use date and storage conditions are published. Whether a milligram dose appears beside the price[1]. On the products surveyed, those last two were published by 18% and 28% respectively[2]. Which of them each seller publishes is recorded on the seller reviews, against the rules in the methodology.